Compare Abbott Laboratories (ABT) vs Noble Corporation plc (NE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Noble Corporation plc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Noble Corporation plc trades at $39.39 (market cap $6.12B). The key difference: Abbott Laboratories is far larger — about 27.3× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (5.21%). Which is the better fit depends on your goals.
| ABT | NE | |
|---|---|---|
Market Cap | $166.94B | $6.12B |
Sector | Health | Technology |
52-Week High | $136.62 | $54.37 |
52-Week Low | $82.57 | $25.70 |
Enterprise Value | $193.69B | $7.37B |
Dividend Yield | 2.63% | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Noble Corporation (NE) trades at $37.41, down 1.53% today, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing in previous quarters. Fundamentals show steady revenue around $3.3 billion with improving net margins to 7.17% in 2026. Noble recently secured a new three-well drilling contract with BP and completed a $800 million senior notes offering to strengthen its financial position.
The stock presents a compelling valuation case with analyst consensus target of $53.33 representing 43% upside potential. However, recent earnings misses and bearish technical signals suggest near-term volatility. The offshore drilling specialist benefits from contract wins and conservative balance sheet management, though execution risks and oil price sensitivity remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
